Coping as a resource to allow for psychosocial adjustment in fatal disease: results from patients with amyotrophic lateral sclerosis.
amyotrophic lateral sclerosis
coping
depressiveness
psychosocial adaptation
quality of life
wellbeing
Journal
Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902
Informations de publication
Date de publication:
2024
2024
Historique:
received:
28
12
2023
accepted:
11
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
epublish
Résumé
Amyotrophic lateral sclerosis (ALS) is a fatal disorder, which imposes a severe emotional burden on patients. Appropriate coping mechanisms may alleviate this burden and facilitate wellbeing, with social support known to be a successful coping strategy. This observational study aimed to determine the interplay of general coping traits of hope for success and fear of failure, coping behavior of social activity, and patients' wellbeing. In this cross-sectional study, patients with ALS from a clinical-epidemiological registry in Southwestern Germany were interviewed regarding coping traits (achievement-motivated behavior: hope for success and fear of failure), coping behavior of social activity, and psychosocial adjustment, determined using measures of depressiveness, anxiety [both measured by Hospital Anxiety and Depression Scale (HADS)], and quality of life [Anamnestic Comparative Self-Assessment (ACSA)]. Demographics, clinical [ALS Functional Rating Scale revised version (ALSFRS-R)], and survival data were recorded. A total of 868 patients [60.70% male patients, mean age: 64.70 (±10.83) years, mean ALSFRS-R: 37.36 ± 7.07] were interviewed. Anxiety in patients was found to be associated with a high fear of failure. In contrast, a generally positive attitude in patients exemplified in high hopes for success was associated with better wellbeing. Finally, coping behavior of social activity explained up to 65% of the variance of depressiveness among the patients with ALS. In this study, we present evidence that the wellbeing of patients with ALS is not an immediate fatalistic consequence of physical degradation but rather determined by coping traits and behavior, which may be trained to substantially increase the wellbeing of patients with ALS.
Sections du résumé
Background
UNASSIGNED
Amyotrophic lateral sclerosis (ALS) is a fatal disorder, which imposes a severe emotional burden on patients. Appropriate coping mechanisms may alleviate this burden and facilitate wellbeing, with social support known to be a successful coping strategy. This observational study aimed to determine the interplay of general coping traits of hope for success and fear of failure, coping behavior of social activity, and patients' wellbeing.
Methods
UNASSIGNED
In this cross-sectional study, patients with ALS from a clinical-epidemiological registry in Southwestern Germany were interviewed regarding coping traits (achievement-motivated behavior: hope for success and fear of failure), coping behavior of social activity, and psychosocial adjustment, determined using measures of depressiveness, anxiety [both measured by Hospital Anxiety and Depression Scale (HADS)], and quality of life [Anamnestic Comparative Self-Assessment (ACSA)]. Demographics, clinical [ALS Functional Rating Scale revised version (ALSFRS-R)], and survival data were recorded.
Results
UNASSIGNED
A total of 868 patients [60.70% male patients, mean age: 64.70 (±10.83) years, mean ALSFRS-R: 37.36 ± 7.07] were interviewed. Anxiety in patients was found to be associated with a high fear of failure. In contrast, a generally positive attitude in patients exemplified in high hopes for success was associated with better wellbeing. Finally, coping behavior of social activity explained up to 65% of the variance of depressiveness among the patients with ALS.
Conclusion
UNASSIGNED
In this study, we present evidence that the wellbeing of patients with ALS is not an immediate fatalistic consequence of physical degradation but rather determined by coping traits and behavior, which may be trained to substantially increase the wellbeing of patients with ALS.
Identifiants
pubmed: 38638511
doi: 10.3389/fpsyg.2024.1361767
pmc: PMC11024296
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1361767Informations de copyright
Copyright © 2024 Finsel, Rosenbohm, Peter, Bäzner, Börtlein, Dempewolf, Schabet, Hecht, Kohler, Opherk, Nägele, Sommer, Lindner, Rothenbacher, Ludolph, Nagel and Lulé.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Références
Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):153-174
pubmed: 28054827
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Psicothema. 2017 Nov;29(4):552-557
pubmed: 29048317
BMC Palliat Care. 2023 Jun 13;22(1):72
pubmed: 37312136
J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):893-8
pubmed: 20587497
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):9-14
pubmed: 23781974
J Neurol Sci. 2012 Sep 15;320(1-2):106-9
pubmed: 22819354
Am Psychol. 1986 Jul;41(7):813-9
pubmed: 3740641
J Pers Soc Psychol. 2007 Dec;93(6):1080-107
pubmed: 18072856
Brain Behav. 2018 Oct;8(10):e01119
pubmed: 30239176
J Neurol. 2022 Feb;269(2):693-702
pubmed: 33783642
J Neurol Sci. 1999 Oct 31;169(1-2):13-21
pubmed: 10540002
J Neurol. 2013 Nov;260(11):2836-43
pubmed: 23989341
Neurology. 2016 Oct 18;87(16):1737-1738
pubmed: 27664982
J Neurol Sci. 2008 Dec 15;275(1-2):69-73
pubmed: 18721928
J Neurol. 2020 Dec;267(12):3593-3601
pubmed: 32638110
Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Dec;3(4):225-31
pubmed: 12710513
Int J Environ Res Public Health. 2022 Feb 10;19(4):
pubmed: 35206143
J Clin Nurs. 2009 Mar;18(5):745-54
pubmed: 19239541
Amyotroph Lateral Scler. 2012 Oct;13(6):599-601
pubmed: 22881411
J Neurol Sci. 2001 Oct 15;191(1-2):79-85
pubmed: 11676996
BMC Neurol. 2013 Feb 17;13:22
pubmed: 23414001
Qual Life Res. 2023 Aug;32(8):2235-2246
pubmed: 36929475
Muscle Nerve. 2019 Jul;60(1):47-55
pubmed: 30897219
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Eur J Neurol. 2012 Mar;19(3):360-75
pubmed: 21914052
Psychol Bull. 2020 Apr;146(4):279-323
pubmed: 31944795
Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291-2
pubmed: 26121170
J Neurol Sci. 2016 Feb 15;361:235-42
pubmed: 26810549
Online J Public Health Inform. 2020 May 16;12(1):e1
pubmed: 32547678
Neurology. 2019 Sep 3;93(10):e938-e945
pubmed: 31391247
Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):374-6
pubmed: 27027323
J Neurol Sci. 2007 Jul 15;258(1-2):4-10
pubmed: 17445834
Eur J Neurol. 2016 Jan;23(1):30-8
pubmed: 26423203
Psychosom Med. 2000 Mar-Apr;62(2):271-9
pubmed: 10772408
J Palliat Med. 2003 Jun;6(3):417-24
pubmed: 14509487
Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16(1-2):16-23
pubmed: 25292386
Psychother Psychosom Med Psychol. 2002 Mar-Apr;52(3-4):141-50
pubmed: 11941521
Front Psychol. 2015 Sep 14;6:1197
pubmed: 26441696
Bioethics. 1999 Jul;13(3-4):272-87
pubmed: 11657238
Annu Rev Public Health. 2002;23:151-69
pubmed: 11910059
CNS Drugs. 2007;21(4):279-91
pubmed: 17381183
Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23
pubmed: 19922118
J Pain Symptom Manage. 2017 Oct;54(4):514-522
pubmed: 28716616
J Neurol. 2017 Apr;264(4):749-757
pubmed: 28220290